Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP3A4 | P08684 | 5/20 | 0.71 |
| ▸ | MAOA | P21397 | 4/20 | 0.71 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.71 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.71 |
| ▸ | CYP2A6 | P11509 | 2/20 | 0.71 |
| ▸ | ACHE | P22303 | 2/20 | 0.71 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.71 |
| ▸ | TSHR | P16473 | 1/20 | 0.71 |
| ▸ | PDE4A | P27815 | 1/20 | 0.71 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.71 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.71 |
| ▸ | CYP2A13 | Q16696 | 1/20 | 0.71 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.68 |
| ▸ | BACE1 | P56817 | 2/20 | 0.68 |
| ▸ | GAA | P10253 | 2/20 | 0.68 |
| ▸ | ABCB1 | P08183 | 1/20 | 0.68 |
| ▸ | CYP1B1 | Q16678 | 1/20 | 0.68 |
| ▸ | RECQL | P46063 | 1/20 | 0.68 |
| ▸ | KCNA3 | P22001 | 3/20 | 0.64 |
| ▸ | KCNA5 | P22460 | 2/20 | 0.64 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9184365 | 0.89 | MAOA (0.76) | CYP3A4MAOACYP1A2CYP2D6CYP2A6 | |
| SCHEMBL18788617 | 0.87 | MAOA (0.78) | CYP3A4MAOACYP1A2CYP2D6CYP2A6 | |
| SCHEMBL7781220 | 0.86 | CYP3A4 (0.72) | CYP3A4MAOACYP1A2CYP2D6CYP2A6 | |
| SCHEMBL18788613 | 0.85 | MAOA (0.74) | CYP3A4MAOACYP1A2CYP2D6CYP2A6 | |
| SCHEMBL18788619 | 0.85 | MAOA (0.74) | CYP3A4MAOACYP1A2CYP2D6CYP2A6 | |
| SCHEMBL20278633 | 0.85 | ALDH1A1 (0.61) | CYP3A4MAOACYP1A2CYP2D6CYP2A6 | |
| SCHEMBL18788581 | 0.85 | CA9 (0.70) | CYP3A4MAOACYP1A2CYP2D6CYP2A6 | |
| SCHEMBL13920857 | 0.84 | MAOA (0.69) | CYP3A4MAOACYP1A2CYP2D6CYP2A6 | |
| Methoxsalen SCHEMBL2302069 | 0.83 | CYP3A4 (1.00) | CYP3A4MAOACYP1A2CYP2D6CYP2A6 | |
| Methoxsalen SCHEMBL29376525 | 0.83 | CYP3A4 (1.00) | CYP3A4MAOACYP1A2CYP2D6CYP2A6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0702568-A1 | AN EMOLLIENT COMPOSITION | BIOGLAN IRELAND (R & D) LIMITED (IE) | 1996-03-27 | — | — | EP | claimed |
| WO-1992017208-A1 | AN EMOLLIENT COMPOSITION | BIOGLAN LABORATORIES LTD. (GB) | 1992-10-15 | — | — | WO | claimed |
| US-20180169433-A1 | METHODS AND SYSTEMS FOR TREATING CELL PROLIFERATION DISORDERS WITH PSORALEN DERIVATIVES | IMMUNOLIGHT, LLC (US) | 2018-06-21 | — | — | US | disclosed |
| US-20180169433-A1 | METHODS AND SYSTEMS FOR TREATING CELL PROLIFERATION DISORDERS WITH PSORALEN DERIVATIVES | IMMUNOLIGHT, LLC (US) | 2018-06-21 | — | — | US | disclosed |
| US-20170113061-A1 | METHODS AND SYSTEMS FOR TREATING CELL PROLIFERATION DISORDERS WITH PSORALEN DERIVATIVES | IMMUNOLIGHT, LLC (US) | 2017-04-27 | — | — | US | disclosed |
| US-20160129027-A1 | CLEAVABLE DRUG CONJUGATES, COMPOSITIONS THEREOF AND METHODS OF USE | Nguyen, Mark Quang (US) | 2016-05-12 | — | — | US | disclosed |
| US-9295731-B2 | Cleavable drug conjugates, compositions thereof and methods of use | Nguyen, Mark Quang (US) | 2016-03-29 | — | — | US | disclosed |
| US-20140294851-A1 | CLEAVABLE DRUG CONJUGATES, COMPOSITIONS THEREOF AND METHODS OF USE | Nguyen, Mark Quang (US) | 2014-10-02 | — | — | US | disclosed |
| US-20140249319-A1 | CHEMICAL CROSSLINKERS AND COMPOSITIONS THEREOF | Nguyen, Mark Quang (US) | 2014-09-04 | — | — | US | disclosed |
| US-20090258381-A1 | Methods for Determining the Cleavability of Substrates | FORSCHUNGSZENTRUM BORSTEL (DE) | 2009-10-15 | — | — | US | disclosed |
| EP-0788345-A1 | PROTEINACEOUS MATERIALS AND FORMULATIONS FOR SUNBURN CELL PROTECTION | NURTURE, Inc. (US) | 1997-08-13 | — | — | EP | disclosed |
| EP-0702568-A1 | AN EMOLLIENT COMPOSITION | BIOGLAN IRELAND (R & D) LIMITED (IE) | 1996-03-27 | — | — | EP | disclosed |
| WO-1995011663-A1 | PROTEINACEOUS MATERIALS AND FORMULATIONS FOR SUNBURN CELL PROTECTION | NURTURE, INC. (US) | 1995-05-04 | — | — | WO | disclosed |
| WO-1992017208-A1 | AN EMOLLIENT COMPOSITION | BIOGLAN LABORATORIES LTD. (GB) | 1992-10-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160129027-A1 | CLEAVABLE DRUG CONJUGATES, COMPOSITIONS THEREOF AND METHODS OF USE | PAICS, FOLH1, DHFR | CYP3A4 675/4885MAOA 1095/4885CYP1A2 1847/4885 |
| US-20140249319-A1 | CHEMICAL CROSSLINKERS AND COMPOSITIONS THEREOF | CBR3, ERCC5, LIG3 | CYP3A4 1525/4885MAOA 1267/4885CYP1A2 1402/4885 |
| US-20140294851-A1 | CLEAVABLE DRUG CONJUGATES, COMPOSITIONS THEREOF AND METHODS OF USE | PAICS, FOLH1, DHFR | CYP3A4 675/4885MAOA 1095/4885CYP1A2 1847/4885 |
| US-20170113061-A1 | METHODS AND SYSTEMS FOR TREATING CELL PROLIFERATION DISORDERS WITH PSORALEN DERIVATIVES | NFATC1, CDK10, CDK20 | CYP3A4 2797/4885MAOA 1698/4885CYP1A2 2315/4885 |
| US-20090258381-A1 | Methods for Determining the Cleavability of Substrates | CTSF, ADAM17, ADAM10 | CYP3A4 283/4885MAOA 742/4885CYP1A2 738/4885 |
| US-20180169433-A1 | METHODS AND SYSTEMS FOR TREATING CELL PROLIFERATION DISORDERS WITH PSORALEN DERIVATIVES | NFATC1, CDK10, PDCD10 | CYP3A4 2619/4885MAOA 1133/4885CYP1A2 2165/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.